62757Priming the AI-Contractome for COVID-19ClosedFeasibility StudiesInnovate UKReturning to a 'normally' functioning global society post COVID-19 will require effective drugs and vaccines, particularly if we are unable to develop long-term immunity to the virus. Hospital studies have shown us that COVID-19 weakens the heart, leading to more severe consequences, so we must ensure that the new drugs we develop to fight COVID-19 do not also damage the heart. It is paramount that these new drugs are safe enough to be used at home as well as hospital and by people who do not know they have COVID-19 or may already have underlying heart conditions and are at increased risk. Our project will enable Pharmaceutical companies to design new COVID-19 drugs that are 'heart safe' faster and with greater chance of success. Extension of Impact Project Following on from successful completion of the original project, global pharmaceutical companies have agreed to engage in ‘Extension of Impact’ pilot studies/beta tests. These will provide impactful case studies, encourage other Pharma Co.’s to adopt our technology, accelerate product sales and develop new COVID-19 drugs that are 'heart safe' faster and with greater chance of success.